EBEdimar Alcides Bocchi

Edimar Alcides Bocchi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Edimar Alcides Bocchi has a total of 671 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Diretriz Brasileira de Insuficiência Cardíaca – 2026

    by Marcus Vinicius Simões, Marcus Vinicius, Lidia Zytynski Moura, Silvia Marinho Martins Alves, Ricardo Mourilhe-Rocha, Luiz Claudio Danzmann, José Albuquerque de Figueiredo Neto, Fabiana Goulart Marcondes-Braga, Mucio Tavares de Oliveira Junior, Denilson Campos de Albuquerque, et al.

    Sumário […] Diretriz Brasileira de Insuficiência Cardíaca – 2026 Sumário […] Diretriz Brasileira de Insuficiência Cardíaca – 2026

  • Open Access

    Biomarkers and arterial stiffness. A sub-analysis of the “Exercise training in heart failure with reduced ejection fraction and permanent atrial fibrillation: A randomized clinical trial”

    by Guilherme Veiga Guimarães, Veridiana Moraes D’ Avila, Paulo Roberto Chizzola, Cristian Alvarez, Edimar Alcides Bocchi

  • Open Access

    Prognostic factors related to all-cause mortality in very long-term follow-up of patients with heart failure: the REMADHE trial extended analysis

    by Edimar Alcides Bocchi, Guilherme Veiga Guimaraes, Cristhian Espinoza Romero, Silvia Moreira Ayub Ferreira, Bruno Biselli, Paulo Roberto Chizzola, Robinson Tadeu Munhoz, Julia Tizue Fukushima, André Rodrigues Durães, Leonardo Roever, et al.

    Background: Disease management programs (DMP) have reduced hospitalizations and improved quality of life in heart failure (HF). However, prognostic factors and survival in very long-term follow-up (> 20 years) have not been reported. Aims: To evaluate the long-term effects of a disease management program (DMP) on heart failure outcomes and to identify prognostic predictors of all-cause mortality in patients with HF followed for up to 23.6 years. Methods: The REMADHE trial (NCT00505050, 2007-07-20) was a prospective, single-center, randomized trial ( n = 412) comparing DMP versus usual care (C) with initial follow-up of 2.47 years. This extended analysis followed patients for 23.6 years to identify prognostic predictors of all-cause mortality. Results: The all-cause mortality rate was 88.3%. HF was the first cause of death followed by sudden death. Mortality was higher in the first 6-year follow-up. The predictive variables in multivariate analysis associated with mortality were age > 52 years ( P = 0.015), Chagas etiology ( P = 0.010), LVEF < 45% ( P = 0.008), digoxin use ( P = 0.002), NYHA IV ( P = 0.01), blood urea nitrogen (BUN) ( P = 0.03), and lymphopenia ( P = 0.005). In very long-term follow-up, DMP did not affect mortality in patients under guideline-directed medical therapy (GDMT). HF as a cause of death was more frequent in the C group (41.0% vs. 33.3% in the DMP group; P < 0.02). Conclusions: DMP was not effective in reducing very long-term mortality; however, causes of death differed between groups, with more HF-related deaths in controls. Our findings that age, LVEF, Chagas’ disease, NYHA, renal function, lymphocytes, and digoxin use were associated with poor prognosis could influence future strategies to improve HF management.

  • Open Access

    Prognostic Factors Related to All-Cause Mortality in Very Long-term Follow-up of Patients with Heart Failure: The REMADHE Trial Extended Analysis

    by Edimar Alcides Bocchi, Guilherme Veiga Guimaraes, Cristhian Espinoza Romero, Silvia Moreira Ayub Ferreira, Bruno Biselli, Paulo Roberto Chizzola, Robinson Tadeu Munhoz, Julia Tizue Fukushima, André Rodrigues Durães, Leonardo Roever, et al.

    Background Disease management programs (DMP) have reduced hospitalizations and improved quality of life in heart failure (HF). However, prognostic factors and survival in very long-term follow-up (> 20 years) have not been reported. Aims To identify prognostic predictors of all-cause mortality in patients with HF followed for 23.6 years. Methods The REMADHE trial (NCT00505050, 2007-07-20) was a prospective, single-center, randomized trial (n = 412) comparing DMP versus usual care (C) with initial follow-up of 2.47 years. This extended analysis followed patients for 23.6 years to identify prognostic predictors of all-cause mortality. Results The all-cause mortality rate was 88.3%. HF was the first cause of death followed by sudden death. Mortality was higher in the first 6-year follow-up. The predictive variables in multivariate analysis associated with mortality were age > 52 years (P = 0.015), Chagas etiology (P = 0.010), LVEF < 45% (P = 0.008), digoxin use (P = 0.002), NYHA IV (P = 0.01), blood urea nitrogen (BUN) (P = 0.03), and lymphopenia (P = 0.005). In very long-term follow-up, DMP did not affect mortality in patients under guideline-directed medical therapy (GDMT). HF as a cause of death was more frequent in the C group. Conclusions DMP was not effective in reducing very long-term mortality; however, causes of death differed between groups, with more HF-related deaths in controls. Our findings that age, LVEF, Chagas' disease, NYHA, renal function, lymphocytes, and digoxin use were associated with poor prognosis could influence future strategies to improve HF management.

  • Open Access

    The Heart Transplant Prioritization System in Brazil: Challenges and Perspectives on the Use of Home Inotropes

    by Helena Garcia Betinardi Bernardi, Edimar Alcides Bocchi

    Introduction Despite advances in the treatment of heart failure with reduced ejection fraction (HFrEF), the disease still represents a significant clinical challenge, especially in advanced stages. It is estimated that up to 13% of patients do not respond to conventional therapies, progressing to severe forms of the syndrome, which are associated with high morbidity and mortality., Globally, about 64 million people live with HF, and in Brazil, 941,576 hospitalizations due to HF were recorded between 2019 and 2023, with a [...] Introduction Despite advances in the treatment of heart failure with reduced ejection fraction (HFrEF), the disease still represents a significant clinical challenge, especially in advanced stages. It is estimated that up to 13% of patients do not respond to conventional therapies, progressing to severe forms of the syndrome, which are associated with high morbidity and mortality., Globally, about 64 million people live with HF, and in Brazil, 941,576 hospitalizations due to HF were recorded between 2019 and 2023, with a

  • Open Access

    O Sistema de Priorização de Transplante Cardíaco no Brasil: Desafios e Perspectivas sobre o uso de inotrópicos domiciliares

    by Helena Garcia Betinardi Bernardi, Edimar Alcides Bocchi

    Introdução Apesar dos avanços no tratamento da insuficiência cardíaca com fração de ejeção reduzida (ICFEr), a doença ainda representa um desafio clínico significativo, especialmente nos estágios avançados. Estima-se que até 13% dos pacientes não respondam às terapias convencionais, evoluindo para formas graves da síndrome, associadas à alta morbimortalidade., Globalmente, cerca de 64 milhões de pessoas vivem com IC e, no Brasil, foram registradas 941 576 internações por IC entre 2019 e 2023, com um aumento progressivo no período. Em 2023, [...] Introdução Apesar dos avanços no tratamento da insuficiência cardíaca com fração de ejeção reduzida (ICFEr), a doença ainda representa um desafio clínico significativo, especialmente nos estágios avançados. Estima-se que até 13% dos pacientes não respondam às terapias convencionais, evoluindo para formas graves da síndrome, associadas à alta morbimortalidade., Globalmente, cerca de 64 milhões de pessoas vivem com IC e, no Brasil, foram registradas 941 576 internações por IC entre 2019 e 2023, com um aumento progressivo no período. Em 2023,

  • Open Access

    Reverse Remodelling, Myocardial Recovery and Remission in Heart Failure with Reduced Ejection Fraction: Clinical Implications and Management Strategies

    by Silas Ramos Furquim, Maria Tereza Sampaio de Sousa Lira, Deborah de Sá Pereira Belfort, Bruno Biselli, Paulo Roberto Chizzola, Robinson Tadeu Munhoz, Edimar Alcides Bocchi, Silvia Moreira Ayub-Ferreira

    Cardiac reverse remodelling (RR) is a complex process involving structural and functional recovery of the myocardium, with significant implications for the prognosis of patients with heart failure (HF). This review summarises current concepts, underlying mechanisms, therapeutic strategies, and clinical implications of RR, while distinguishing it from myocardial recovery and remission. Both pharmacological therapies and non-pharmacological interventions have shown potential to induce RR in selected populations. Clinical features, echocardiographic parameters, advanced imaging findings, and biomarkers help stratify patients according to the likelihood of recovery and risk of relapse. The management of HF with improved ejection fraction remains debated. High recurrence rates are seen after therapy discontinuation; however, evidence suggests that partial withdrawal may be safe in specific patient profiles. RR should be considered a central therapeutic goal in HF care, although its extent and stability vary widely. Differentiating between transient improvement, remission under therapy, and true myocardial recovery is critical for guiding long-term treatment decisions, highlighting the importance of individualised follow-up.


  • Open Access

    Reversão de Hipertensão Pulmonar Tipo 2 após o Uso de Levosimendan: Uma Abordagem Desafiadora Trazendo Novas Perspectivas

    by Helena Garcia Betinardi Bernardi, Deborah de Sá Pereira Belfort, Bruno Biselli, Paulo Roberto Chizzola, Robinson Tadeu Munhoz, Silvia M. Ayub-Ferreira, Edimar Alcides Bocchi

    Dentre os inotrópicos utilizados no manejo de insuficiência cardíaca, o levosimendan, em particular, possui uma propriedade venodilatadora seletiva que parece explicar seu benefício clínico durante a hipertensão pulmonar (HP). A maioria das evidências se refere a pacientes com HP do grupo 2 e consequente disfunção do ventrículo direito (VD). Neste cenário, os benefícios observados podem ser devido ao efeito do levosimendan na contratilidade do VD e na dilatação dos vasos pulmonares, ou à melhora da função ventricular esquerda e consequente redução da congestão pulmonar. O que percebemos é que cada vez se estuda mais sobre essa ação e aplicabilidade da droga, aparecendo em pequenos estudos, revisões e indicações formais.

  • Open Access

    Reversal of Type 2 Pulmonary Hypertension after Levosimendan: A Challenging Approach Bringing New Insights

    by Helena Garcia Betinardi Bernardi, Deborah de Sá Pereira Belfort, Bruno Biselli, Paulo Roberto Chizzola, Robinson Tadeu Munhoz, Silvia M. Ayub-Ferreira, Edimar Alcides Bocchi

    Among the inotropic agents used in the management of heart failure, levosimendan, in particular, has a selective venodilator property that appears to explain its clinical benefit during pulmonary hypertension (PH). Most of the evidence refers to patients with group 2 PH and consequent right ventricular (RV) dysfunction. In this scenario, the observed benefits may be due to the effect of levosimendan on RV contractility and pulmonary vessel dilation, or to the improvement of left ventricular function and consequent reduction [...] Abstract Among the inotropic agents used in the management of heart failure, levosimendan, in particular, has a selective venodilator property that appears to explain its clinical benefit during pulmonary hypertension (PH). Most of the evidence refers to patients with group 2 PH and consequent right ventricular (RV) dysfunction. In this scenario, the observed benefits may be due to the effect of levosimendan on RV contractility and pulmonary vessel dilation, or to the improvement of left ventricular function and consequent reduction

  • Open Access

    Association of potassium disorders with the mode of death and etiology in patients with chronic heart failure: the INCOR-HF study

    by Ivna G C V Lima, Jairo T Nunes, Igor H de Oliveira, Silvia M A Ferreira, Robinson T Munhoz, Paulo R Chizzola, Bruno Biselli, Brenno R Gomes, Lucas P Damiani, André S Maria, et al.

    Observational studies suggest a U-shaped association between serum potassium (K⁺) levels and mortality in patients with chronic heart failure (CHF). However, the mode of death in patients with HF and K⁺ disorders remains speculative. To investigate the association between potassium disorders and the mode of death in patients with CHF. A retrospective cohort of 10,378 CHF outpatients was analyzed over an average of 3.28 ± 2.5 years. Kaplan-Meier method, Cox proportional hazards regression models, Poisson regression models adjusting for confounders, and e-value determination (e' > 1.6) were used to observe associations between potassium disorders and outcomes. Chagas etiology (p < 0.01) and triple HF therapy (p < 0.01) were associated with hyperkalemia. Atrial fibrillation was associated with hypokalemia (p < 0.01). Chronic kidney disease (CKD) (p < 0.01) and diabetes (p = 0.03) were associated with both. Hypertension was inversely related to hyperkalemia (p < 0.01); age was inversely related to hypokalemia. Associations with mortality were significant for Chagas (p < 0.01, e-value 2.16), stroke (p < 0.01, e-value 1.85), hypokalemia (p = 0.02, e-value 1.94), severe hyperkalemia (p = 0.08, e-value 1.93), and CKD (p < 0.01, e-value > 1.63). Decompensated HF or cardiogenic shock was the cause of death in 54% of patients with normokalemia, 67.8% with hypokalemia, 44.9% with mild hyperkalemia, 57.8% with moderate hyperkalemia, and 69% with severe hyperkalemia. Most patients with hypokalemia and severe hyperkalemia died from decompensated HF (p = 0.007). Data suggest hypokalemia and severe hyperkalemia, along with Chagas and CKD, are associated with death. Unexpectedly, progressive HF was the most frequent mode of death rather than arrhythmias. Further studies are needed to confirm these findings and explore the underlying mechanisms.